


Collaborating with Industry: The Good, The Bad and The Ugly

Professor Andrew Hughes MA PhD MRCP FFPM PGDip

**Chair, Experimental Cancer Medicine, University of Manchester
Strategic Director Experimental Cancer Medicine, The Christie**

ECMC Annual Network Meeting
Thursday May 21st 2015

Good Collaborations=interdependency
A win-win and loose-loose



...but predicting future needs thus interdependency can be tricky!

**Potential ECMC
Capabilities needed**

**Possible
Interaction models**

Precision Medicine



Capabilities needed

Technologies for stratification

Multi-arm clinical studies

“Niche” populations available

Interaction models

National qualification centres

Inter-sponsor collaborations

ECMC Network = ECMUK

Patient Centricity



Capabilities needed

Trial on a Smartphone

24h clinical trial data capture
and review

Patients!

Interaction models

Funding calls

Software PLC/Regulatory

Chief Patient Officer

Scientific understanding



| Capabilities needed | Interaction models |
|-----------------------|--|
| Inquisitive Profiling | Investigator-led Research & “Macro dosing” |
| Porosity | Collaborative workspaces & capability transparency |
| Data Interoperability | Standards across network |

Great Science *AND* Great Relationships

